

Peter Kowey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1047709/publications.pdf>

Version: 2024-02-01

139
papers

8,286
citations

76326

40
h-index

48315

88
g-index

140
all docs

140
docs citations

140
times ranked

9320
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies. <i>Clinical Cardiology</i> , 2022, 45, 119-128.	1.8	0
2	Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS&ADONIS trials. <i>Clinical Cardiology</i> , 2022, 45, 101-109.	1.8	1
3	Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010204.	4.8	8
4	AIM&AF: A Physician Survey in the United States and Europe. <i>Journal of the American Heart Association</i> , 2022, 11, e023838.	3.7	10
5	Increased susceptibility to ventricular arrhythmia at low-normal and moderately-low levels of extracellular potassium in Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Heart Rhythm</i> , 2022, , .	0.7	0
6	Patterns of oral anticoagulation use with cardioversion in clinical practice. <i>Heart</i> , 2021, 107, 642-649.	2.9	3
7	Use of the HAVOC Score to Identify Patients at Highest Risk of Developing Atrial Fibrillation. <i>Cardiology</i> , 2021, 146, 633-640.	1.4	4
8	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 553-561.	2.2	5
9	A most remarkable person: Dr Bernard Lown. <i>European Heart Journal</i> , 2021, 42, 1938-1939.	2.2	0
10	Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation With Inserted Cardiac Monitors. <i>American Journal of Cardiology</i> , 2021, 145, 64-68.	1.6	3
11	Corroboration equals collaboration. <i>Heart Rhythm</i> , 2021, 18, 682-683.	0.7	0
12	Reexamination of the Embolic Stroke of Undetermined Source Concept. <i>Stroke</i> , 2021, 52, 2715-2722.	2.0	9
13	Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk. <i>Heart Rhythm</i> , 2021, 18, 2177-2186.	0.7	2
14	Cherry-picking atrial fibrillation ablation responders: Can antiarrhythmic drugs help?. <i>Heart Rhythm</i> , 2021, 18, 1480-1481.	0.7	0
15	Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e010063.	4.8	23
16	Medicine on Twitter. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009434.	4.8	0
17	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. <i>American Heart Journal</i> , 2020, 220, 145-154.	2.7	3
18	Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. <i>American Heart Journal</i> , 2020, 219, 128-136.	2.7	12

#	ARTICLE	IF	CITATIONS
19	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007775.	4.8	6
20	The Relentless Pursuit of New Drugs to Treat Cardiac Arrhythmias. <i>Circulation</i> , 2020, 141, 1507-1509.	1.6	4
21	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2020, 226, 85-93.	2.7	13
22	Abstract 15742: An Open-label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution Shows Acute Conversion of Recent-onset, Symptomatic Atrial Fibrillation to Sinus Rhythm in a Dose- and Concentration-dependent Manner. <i>Circulation</i> , 2020, 142, .	1.6	0
23	Abstract 12785: The American College of Cardiology's NCDR Afib Ablation Registry: A Summary of Initial Data Including Patient Characteristics, Procedural Characteristics, and Adverse Events. <i>Circulation</i> , 2020, 142, .	1.6	0
24	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. <i>Heart</i> , 2019, 105, heartjnl-2018-313642.	2.9	22
25	Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. <i>International Journal of Cardiology</i> , 2019, 274, 152-157.	1.7	7
26	A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 21-28.	3.0	20
27	Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). <i>American Journal of Cardiology</i> , 2019, 124, 864-870.	1.6	4
28	Strategies to Reduce Recurrent Shocks Due to Ventricular Arrhythmias in Patients with an Implanted Cardioverter-Defibrillator. <i>Arrhythmia and Electrophysiology Review</i> , 2019, 8, 99-104.	2.4	3
29	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 756.	6.1	10
30	The Evolution of the One-Armed Bandit. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2376-2378.	2.8	2
31	Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 381, 1909-1917.	27.0	1,100
32	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. <i>American Heart Journal</i> , 2019, 213, 81-90.	2.7	10
33	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005358.	2.2	59
34	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1261.	7.4	953
35	Atrial Fibrillation Ablation Should Be First-Line Therapy in Heart Failure Patients: CON. <i>Cardiology Clinics</i> , 2019, 37, 197-206.	2.2	0
36	Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	1.6	10

#	ARTICLE	IF	CITATIONS
37	Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007612.	4.8	27
38	Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. <i>American Heart Journal</i> , 2019, 207, 66-75.	2.7	311
39	Cardioversion of obese patients: What is the weight of evidence?. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 162-163.	1.7	0
40	Cardiovascular Safety During and After Use of Phentermine and Topiramate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 513-522.	3.6	28
41	Pharmacological Therapy for Ventricular Arrhythmias: A State-of-the Art Review. <i>Heart Lung and Circulation</i> , 2019, 28, 49-56.	0.4	4
42	Cardiovascular Safety of the Selective μ -Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 309-317.	2.0	10
43	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 889-897.	1.6	23
44	Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	6
45	Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	143
46	Assessing intracardiac thrombus prior to cardioversion: A story yet to be told. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 548-550.	1.7	0
47	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. <i>JAMA Cardiology</i> , 2018, 3, 54.	6.1	77
48	Disease understanding in patients newly diagnosed with atrial fibrillation. <i>Heart</i> , 2018, 104, 494-501.	2.9	25
49	Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1677-1683.	1.6	13
50	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 435-439.	2.1	9
51	Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	12
52	Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial. <i>American Heart Journal</i> , 2017, 185, 43-51.	2.7	10
53	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2017, 189, 40-47.	2.7	53
54	Back to the basics. <i>Heart Rhythm</i> , 2017, 14, 455-456.	0.7	0

#	ARTICLE	IF	CITATIONS
55	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Tj ETQq1 1 0.784314 rgBT/Overlook Journal of Cardiology, 2017, 119, 1590-1595.	1.6	33
56	Acquired long QT syndrome in hospitalized patients. Heart Rhythm, 2017, 14, 974-978.	0.7	42
57	Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. JACC: Heart Failure, 2017, 5, 44-52.	4.1	91
58	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. American Journal of Medicine, 2017, 130, 449-456.	1.5	25
59	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	2.7	161
60	Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population. JAMA Cardiology, 2017, 2, 1120.	6.1	200
61	Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes. Journal of the American College of Cardiology, 2017, 70, 1325-1335.	2.8	124
62	Pharmacological Therapy for Rate and Rhythm Control for Atrial Fibrillation in 2017. Heart Lung and Circulation, 2017, 26, 926-933.	0.4	7
63	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	29
64	The tyranny of numbers, large and small. Journal of Cardiovascular Electrophysiology, 2017, 28, 1443-1444.	1.7	0
65	Cardioversion and subsequent quality of life and natural history of atrial fibrillation. American Heart Journal, 2017, 185, 59-66.	2.7	18
66	Update on atrial fibrillation. Trends in Cardiovascular Medicine, 2017, 27, 14-25.	4.9	29
67	Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. Heart Rhythm, 2017, 14, e41-e44.	0.7	91
68	Regional Lack of Consistency in the Management of Atrial Fibrillation (from the RECORD-AF Trial). American Journal of Cardiology, 2017, 119, 47-51.	1.6	6
69	Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial) Tj ETQq1 1 0.784314 rgBT/Overlook	1.6	43
70	Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. Journal of Atrial Fibrillation, 2017, 9, 1551.	0.5	7
71	Darned If You Do Darned If You Don't. Journal of Cardiovascular Electrophysiology, 2016, 27, 811-812.	1.7	0
72	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. Journal of the American College of Cardiology, 2016, 68, 2597-2604.	2.8	401

#	ARTICLE	IF	CITATIONS
73	Detection of ECG effects of (2R,4R)-monatin, a sweet flavored isomer of a component first identified in the root bark of the Sclerochitin ilicifolius plant. Food and Chemical Toxicology, 2016, 91, 217-224.	3.6	4
74	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men. JAMA Cardiology, 2016, 1, 282.	6.1	182
75	Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. Journal of the American Heart Association, 2016, 5, e002944.	3.7	37
76	Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. Heart Rhythm, 2016, 13, 1777-1783.	0.7	27
77	Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. Journal of the American Heart Association, 2016, 5, .	3.7	16
78	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2016, 181, 145-152.	2.7	13
79	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation, 2016, 134, 1122-1124.	1.6	6
80	Glass Half Empty? —. JACC: Clinical Electrophysiology, 2016, 2, 782-783.	3.2	0
81	Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. Clinical Cardiology, 2016, 39, 119-125.	1.8	6
82	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. American Journal of Medicine, 2016, 129, 592-599.e1.	1.5	49
83	Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation. JACC: Clinical Electrophysiology, 2016, 2, 355-363.	3.2	45
84	Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. American Heart Journal, 2016, 174, 29-36.	2.7	82
85	Status of Antiarrhythmic Drug Development for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e002479.	4.8	20
86	Antiarrhythmic Drug Therapy for Atrial Fibrillation. Heart Failure Clinics, 2016, 12, 205-221.	2.1	21
87	Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures. JACC: Clinical Electrophysiology, 2015, 1, 315-322.	3.2	53
88	Does atrial fibrillation pattern affect stroke risk? Data dredging to help the clinician. European Heart Journal, 2015, 36, 265-266.	2.2	1
89	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. Circulation, 2015, 131, 488-494.	1.6	224
90	Effect of the 2014 Atrial Fibrillation Guideline Revisions on the Proportion of Patients Recommended for Oral Anticoagulation. JAMA Internal Medicine, 2015, 175, 848.	5.1	20

#	ARTICLE	IF	CITATIONS
91	Heterogeneous distribution of INa-L determines interregional differences in rate adaptation of repolarization. <i>Heart Rhythm</i> , 2015, 12, 1295-1303.	0.7	30
92	Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 393-402.	2.2	173
93	Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 486-495.	2.7	21
94	COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. <i>Heart Rhythm</i> , 2015, 12, 1105-1112.	0.7	22
95	Patients'™ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <i>American Heart Journal</i> , 2015, 170, 141-148.e1.	2.7	211
96	Smoothing the Bumpy Road to Antiarrhythmic Drug Development. <i>Circulation</i> , 2015, 132, 2195-2197.	1.6	0
97	Observing the Obvious— <i>Journal of the American College of Cardiology</i> , 2015, 66, 1008-1010.	2.8	0
98	The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. <i>European Heart Journal</i> , 2015, 36, ehv476.	2.2	316
99	The HARMONY Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1048-1056.	4.8	129
100	Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT- <i>AF</i>). <i>Journal of the American Heart Association</i> , 2015, 4, e002031.	3.7	41
101	Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?. <i>Journal of Thoracic Disease</i> , 2015, 7, 165-71.	1.4	44
102	In Memoriam Tribute to Dusan Z. Kocovic, MD. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 990-990.	4.8	0
103	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 896-904.	2.2	52
104	Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>American Heart Journal</i> , 2014, 167, 601-609.e1.	2.7	135
105	Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2014, 113, 888-896.	1.6	9
106	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 2005-2012.	1.6	73
107	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014, 167, 735-742.e2.	2.7	120
108	Antiarrhythmic Drug Therapy for Atrial Fibrillation. <i>Cardiology Clinics</i> , 2014, 32, 533-549.	2.2	6

#	ARTICLE	IF	CITATIONS
109	Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 168, 487-494.	2.7	107
110	The impact of medical malpractice litigation on cardiovascular practice in the US and China. International Journal of Cardiology, 2014, 177, 48-50.	1.7	7
111	Ablation Versus Drugs: What Is the Best First-Line Therapy for Paroxysmal Atrial Fibrillation?. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 747-754.	4.8	9
112	Rationale and design of REVEAL AF: A prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. American Heart Journal, 2014, 167, 22-27.	2.7	32
113	Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry. American Heart Journal, 2014, 168, 160-167.	2.7	62
114	The Role of Dronedaron in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS. Current Cardiology Reviews, 2014, 10, 303-308.	1.5	13
115	Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?. World Journal of Cardiology, 2014, 6, 764.	1.5	18
116	Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD. Chest, 2013, 144, 758-765.	0.8	95
117	Should Physicians Continue to Recommend Fish Oil for Patients with Atrial Fibrillation?. Journal of Atrial Fibrillation, 2012, 5, 593.	0.5	0
118	Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. Circulation, 2011, 124, 2649-2660.	1.6	45
119	Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation. Drugs in R and D, 2011, 11, 1-11.	2.2	19
120	Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. American Heart Journal, 2011, 162, 606-612.e1.	2.7	137
121	How Much Has Malpractice Litigation Altered the Care of Cardiac Rhythm Patients?. Journal of Cardiovascular Electrophysiology, 2011, 22, 488-489.	1.7	2
122	The Silent Majority. JAMA - Journal of the American Medical Association, 2011, 306, 18-9.	7.4	7
123	Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey. Clinical Cardiology, 2010, 33, 172-178.	1.8	13
124	Why Did You Order That Echocardiogram?. Clinical Cardiology, 2010, 33, 596-597.	1.8	0
125	Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry). American Journal of Cardiology, 2010, 105, 1122-1129.	1.6	45
126	Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	1.6	30

#	ARTICLE	IF	CITATIONS
127	Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2010, 304, 2363.	7.4	183
128	Dronedaron for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. New England Journal of Medicine, 2007, 357, 987-999.	27.0	597
129	Cardiac Implantable Electrical Devices in the Elderly: A Promise of Prolonged Survival and an Improved Quality of Life. The American Journal of Geriatric Cardiology, 2006, 15, 75-76.	0.6	0
130	Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches. American Journal of Cardiology, 2003, 91, 33-38.	1.6	106
131	Ambulatory Electrocardiographic Recording. Circulation, 2003, 108, e31-3.	1.6	23
132	I've Fallen and I Can't Get Up. The American Journal of Geriatric Cardiology, 2003, 12, 306-306.	0.6	0
133	Clinical Outcome of Patients Who Develop PAF After CABG Surgery. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 191-193.	1.2	71
134	ST Segment Elevation and Sudden Cardiac Death: From the Brugada Syndrome to Acute Myocardial Ischemia. Journal of Cardiovascular Electrophysiology, 2000, 11, 1330-1332.	1.7	18
135	Electropharmacologic effect of a standard dose of intravenous procainamide in patients with sustained ventricular tachycardia. Clinical Cardiology, 2000, 23, 171-174.	1.8	3
136	A Broken Heart. Circulation, 1998, 98, 1349-1349.	1.6	77
137	Monomorphic Right Ventricular Tachycardia in a Patient with Mitral Valve Prolapse. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 509-513.	1.2	1
138	Device Interaction-Antitachycardia Pacemakers and Defibrillators for Sustained Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 302-307.	1.2	10
139	Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials. Journal of Biopharmaceutical Statistics, 0, , 1-15.	0.8	4